• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Just How Much Healthcare Should We Afford?

by HITC Staff 05/26/2017 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

6 Metrics to Improve Hospital Revenue Cycle ROI_revenue cycle makret

One topic that has been missed in the ongoing debate about health insurance has been the level of care that is available today. There has been very little discussion about the fact that people are routinely surviving unscathed when suffering illnesses or injuries that would have been fatal even just a few decades ago.

The point that could be made is that our high expectations of medical care today are a lot of the reason for the skyrocketing cost. The frontier doctor who would ride to a home on horseback and deliver a baby for a few dollars wasn’t just kind. He also had less overhead. He didn’t request ultrasounds, have a neonatal team on standby and he knew he wouldn’t be performing a Cesarean section.

Today, if an obstetrician’s fee was covered by insurance, but those other things were not, most people would agree that it was a travesty. It’s an issue that has been addressed extensively in end-of-life debates, but the reality is that the skyrocketing cost of care is also tied very closely to the expanding ability to intervene against even less serious injuries and illnesses.

Certainly, there are innovations that are affordable. Medical conditions that reduced mobility once meant a lifelong need for assistance with a wheelchair. Now there are power chairs that can be operated by people with even the most restrictive conditions. From Quingo scooters for arthritic seniors up to “sip and puff” chairs operated by quadriplegics, mobility has been an advancement that’s realistic and beneficial for health insurance to cover.

So, it’s clear that many of today’s innovations are not only beneficial but affordable. The debate, then, is centered around just how much we can afford to provide coverage for, and whether there is a good enough chance for recovery to make that investment worthwhile. This is of particular importance with a new POTUS in office promising to overhaul health care.

But is a simple cost-benefit analysis a realistic and humane way to talk about life? Many argue that healthcare should pay for any treatment that has a chance of saving a life. Yet the standard for what constitutes “saving” a life has been a difficult one to establish.

It is clear that certain options represent viable methods of saving lives that could not have been saved decades ago. Advanced treatments like implanted defibrillators, insulin pumps and organ transplants have proven to be effective for the world’s sickest patients, giving them both quantity and quality of life. They are expensive, but they definitely work.

But what about other treatments? Many things, like ventilators and pressor drugs, are intended to serve as stop-gap measures, techniques that can keep a person viable long enough for an underlying condition to be repaired. Yet these tools are often employed as last-ditch efforts to keep a patient alive with little or no prospect for a meaningful recovery. Even that term–“meaningful recovery”–is debated. 

Still other conditions present a perplexing scenario. Prostate cancer is a good example. It is widely believed in the medical profession that, beyond a certain age, treatment of prostate cancer is pointless. The reasoning is that the disease progresses so slowly that something else will probably kill the patient before the cancer will, and that the course of treatment is so difficult–often leading to incontinence and impotence–it’s not worthwhile. Consequently, blood work to detect prostate cancer is not covered after age 70.

The only thing clear in this whole debate is that a lot of things are unclear. We struggle as a society, and even as individuals, with what constitutes a worthwhile treatment, even without considering the cost. Once financial issues are brought into the discussion, the water becomes even murkier. What is clear is that there will be no satisfactory and effective solution to the national healthcare debate until these issues are addressed with an unanimity that currently seems unlikely.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |